SCHEMBL2355300

SCHEMBL2355300

COCCN(C)c1ccc(C(=O)Nc2nc(-c3ccc(OC)cc3)c(C)s2)cn1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 8/20 0.51
KDM4E B2RXH2 5/20 0.51
MAPK1 P28482 3/20 0.51
HTT P42858 3/20 0.51
PKM P14618 1/20 0.51
SMN1; SMN2 Q16637 7/20 0.51
ALDH1A1 P00352 4/20 0.51
HPGD P15428 2/20 0.51
NPSR1 Q6W5P4 2/20 0.51
RXFP1 Q9HBX9 1/20 0.51
LMNA P02545 6/20 0.49
L3MBTL1 Q9Y468 2/20 0.49
ALOX12 P18054 1/20 0.47
HSD17B10 Q99714 1/20 0.47
PTBP1 P26599 1/20 0.47
ADORA1 P30542 3/20 0.47
ADORA3 P0DMS8 3/20 0.46
RECQL P46063 1/20 0.46
MEN1 O00255 1/20 0.46
THRB P10828 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3313526 0.93 ALDH1A1 (0.50) MAPTKDM4EMAPK1HTTPKM
SCHEMBL3312659 0.91 ALDH1A1 (0.54) KDM4EMAPK1HTTPKMSMN1; SMN2
SCHEMBL2303062 0.81 MAPT (0.55) MAPTKDM4EMAPK1HTTPKM
SCHEMBL13360595 0.80 ALDH1A1 (0.49) MAPTKDM4EMAPK1HTTPKM
SCHEMBL14995137 0.76 ADORA1 (0.71) MAPTKDM4EMAPK1HTTPKM
SCHEMBL12301018 0.76 ALDH1A1 (0.78) MAPTKDM4EMAPK1HTTPKM
SCHEMBL12300978 0.75 MAPT (0.60) MAPTKDM4EMAPK1HTTPKM
SCHEMBL1303838 0.74 SMN1; SMN2 (0.71) MAPTKDM4EMAPK1HTTPKM
SCHEMBL16607171 0.74 KDM4E (0.61) MAPTKDM4EMAPK1HTTPKM
SCHEMBL3311847 0.74 KDM4E (0.68) MAPTKDM4EHTTSMN1; SMN2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2350311-B1 DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS MADRIGAL PHARMACEUTICALS INC (US) 2013-12-25 EP disclosed
US-8324385-B2 Diacylglycerol acyltransferase inhibitors MADRIGAL PHARMACEUTICALS, INC. (US) 2012-12-04 US disclosed
US-8324385-B2 Diacylglycerol acyltransferase inhibitors MADRIGAL PHARMACEUTICALS, INC. (US) 2012-12-04 US disclosed
US-8324385-B2 Diacylglycerol acyltransferase inhibitors MADRIGAL PHARMACEUTICALS, INC. (US) 2012-12-04 US disclosed
EP-2350311-A1 DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS Via Pharmaceuticals, Inc. (US) 2011-08-03 EP disclosed
WO-2010056506-A1 DIACYLGLYCEROL ACLYTRANSFERASE INHIBITORS VIA PHARMACEUTICALS, INC. (US) 2010-05-20 WO disclosed
WO-2010056506-A1 DIACYLGLYCEROL ACLYTRANSFERASE INHIBITORS VIA PHARMACEUTICALS, INC. (US) 2010-05-20 WO disclosed
US-20100113782-A1 Diacylglycerol Acyltransferase Inhibitors MADRIGAL PHARMACEUTICALS, INC. 2010-05-06 US disclosed
US-20100113782-A1 Diacylglycerol Acyltransferase Inhibitors MADRIGAL PHARMACEUTICALS, INC. 2010-05-06 US disclosed
US-20100113782-A1 Diacylglycerol Acyltransferase Inhibitors MADRIGAL PHARMACEUTICALS, INC. 2010-05-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100113782-A1 Diacylglycerol Acyltransferase Inhibitors DGAT2, DGAT1, MOGAT2 MAPT 4008/4885KDM4E 3683/4885MAPK1 2315/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.